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Three hundred and ninety women participated in the quality of life (QL) study of ACCOG1, a high-dose vs conventional adjuvant
chemotherapy breast cancer trial, for patients with a high risk of relapse. Patients completed the European Organisation for Research
and Treatment of Cancer QLQ-C30, questions on menopausal symptoms and the Sexual Activity Questionnaire. Pretreatment, 6,12,
24, 36, 48 and 60-month assessments were conducted. For the high dose group the median decrease in global QL at 6 months was
significantly greater than in the conventional group. At 12 months, however, the median change had returned to 0 for both groups.
Social functioning was also significantly lower in the high-dose group at 6 months, again returning to prebaseline levels for both groups
after 12 months. The most persistent changes appear to be in the effect of treatment in both arms on sexual outcomes, reflected in
problems with discomfort and pleasure. Both high-dose and conventional chemotherapy showed persisting negative effects on sexual
health. This has not been previously reported as a long-term complication of high-dose chemotherapy. However, it did not have long-
term affects on sexual habit, which appeared to return to pretreatment frequency and similar to that of conventional chemotherapy
by about 12 months from treatment.
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Breast cancer patients with four or more positive axillary lymph
nodes have historically had a poor prognosis (Jatoi et al, 1999),
even with conventional adjuvant chemotherapy (EBCTCG, 2005).
A series of uncontrolled studies of high-dose chemotherapy in the
1990s, mainly using an induction/intensification strategy, in which
patients received conventional chemotherapy followed by high-
dose chemotherapy as a late intensification regimen, produced
results that showed a substantial benefit for high-dose regimens
(Antman et al, 1992; Peters et al, 1993). High-dose therapy soon
became a widely used treatment option for women with bad-risk
breast cancer, even without supporting evidence from randomised
controlled trials.
The Anglo Celtic 1 trial was set up to examine the potential
benefit, if any, of employing high-dose chemotherapy in the
treatment of early stage bad-risk breast cancer based on
the involvement of the axillary nodes at diagnosis. One of the
prospective substudies within the Anglo-Celtic 1 trial was to
examine the impact of late intensification high-dose chemotherapy
on QL. The purpose of this report is to review the detailed analysis
of patient QL. Ethical approval for all parts of the study was given
from the MREC for Scotland.
PATIENTS AND METHODS
Between February 1995 and June 1999, 605 patients with newly
diagnosed breast cancer with four or more positive lymph nodes
were randomly assigned to either conventional (n¼298) or high-
dose treatment (n¼307). Both treatment arms initially received
four cycles of doxorubicin 75mgm
 2. Patients in the conventional
arm then received eight further cycles of CMF (cyclophosphamide
(600mgm
 2), methotrexate (50mgm
 2) and 5-fluorouracil
(600mgm
 2) while the high-dose group received a single cycle
of intermediate-dose cyclophosphamide (4000mgm
 2) supported
by filgrastim (300mgday
 1) for up to 10 days followed by high-
dose cyclophosphamide (6000mgm
 2) and thiotepa (800mgm
 2).
Peripheral blood progenitor cells were harvested by leukapheresis
after treatment with cyclophosphamide and filgrastim and re-
infused after the high-dose cycle. A full report of the main study
has been published (Leonard et al, 2004).
Quality of Life
The two arms of the trial differed in two ways with regard to QL.
In the conventional arm, therapy continued over a much longer
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speriod – 9 months vs 4 months in the high-dose arm. But in the
high-dose arm treatment was more intense with the risk of severe
short-term side effects. It was decided that QL would be compared
initially at 6 months following the start of treatment. Those on the
high-dose regimen would have completed their treatment, while
patients in the conventional arm were still having treatment. It was
planned that later assessments would give an indication of the
global QL of all patients having completed their treatment and,
importantly, as adjuvant chemotherapy regimens that include
cyclophosphamide have been reported to induce high levels of
premature menopause (Bines et al, 1996), the effects of these
treatments on menopausal symptoms and sexual function. The
main aims of the QL study were to assess and compare the two
groups with respect to their reported:
1. global QL
2. fatigue
3. menopausal symptoms
4. sexual function.
Instruments
QLQ-C30 The EORTC QLQ-C30 (Aaronsen et al, 1993) is a 30-
item self-report questionnaire that incorporates functional scales
(physical, role, emotional and social) a global QL scale, 3-symptom
scales (fatigue, pain, nausea and vomiting) and a number of single
item measures. Published data show its practicality, reliability and
validity in a variety of patient groups (Osoba et al, 1994: Apolone
et al, 1998). The QLQ-C30 has been used extensively in studies
with breast cancer patients. The global QL and fatigue scales were
considered of particular relevance to this study (Curt, 2000; Cella
et al, 2004). Also, the ratio of cost to the patient (side effects) to the
benefit (disease control/survival) is crucial to the evaluation of
treatment worth. Assessment of global QL is derived from two
items concerning overall health and global QL rated on a 7-point
scale (very poor to excellent). Item scores are summed and linearly
transformed (0–100). A higher score represents a better quality of
life. The fatigue scale consists of three items (concerned with need
for rest, weakness and tiredness), each scored on a 4-point scale
(not at all to very much). Item scores are summed and linearly
transformed (0–100). A high score represents a higher level of
fatigue.
Menopausal symptoms Menopausal symptoms are not ade-
quately monitored by the QLQ-C30, therefore additional items
were required. The items chosen were derived following consulta-
tion with clinicians involved in the ABC trial – following a review
of the literature and of the women’s health questionnaire. The
items selected concerned the experience of termination of
menstruation, night sweats, day sweats, vaginal dryness, weight
gain, and aches and pains. These were adapted to conform to the
response format of the EORTC questionnaire.
Sexual activity questionnaire Sexual function is a difficult
dimension of QL to assess by self-report questionnaire and
responses are likely to reflect affective and interpersonal factors
as well as their psychological status. Because of the importance
attached to improving understanding of sexual outcomes, it was
decided to incorporate the Sexual Activity Questionnaire (SAQ)
into this study. The SAQ (Thirlaway et al, 1996) was developed for
another study (Fallowfield et al, 2001) and is designed to measure
sexual functioning in terms of activity, pleasure and discomfort.
Assessment schedule Quality of life measures were assessed
before randomisation, at 6 months, 1 year and annually thereafter
up to 5 years. Questionnaires were administered by research
nurses at the recruiting centres. Follow-up for QL ceased if a breast
cancer recurrence was diagnosed.
Study population
Eligible patients were patients who were entered into the high dose
vs conventional adjuvant chemotherapy breast cancer trial
(ACCOG1) trial were able and willing to give informed consent
to participate in the QL study and able to read and complete the
self-report QL questionnaire. Three hundred and ninety patients
from 27 centres completed at least one QL questionnaire.
Statistical methods
All statistical tests were two-sided. Tests were reported as
significant if Po0.05. No formal adjustments were made for
multiple testing but P-values were reported to allow judgement to
be used in the interpretation of the results. Scores were compared
between treatment groups using the Mann–Whitney test. Changes
over time in scores were calculated per patient and hence tests
were restricted to those patients responding at both of the time
points on question. Proportions were compared using Fisher’s
exact test. Changes in proportions over time were compared using
the McNemar test (to allow for the pairing of binary responses in
an individual patient).
RESULTS
Patient characteristics
Demographic data and clinical characteristics of the two groups
within the QL study were compared to those of all study patients
(Table 1). Mean age of all patients in the QL study was 45 years
for high dose and 46 for conventional therapy patients. At the start
of the study, 67% of patients in the high-dose arm and 63% of
patients on conventional therapy were known to be premeno-
pausal, with 80 and 79% of all patients receiving tamoxifen,
respectively.
Response rate
Table 2 shows the numbers of QL forms returned at each time
point, compared with the numbers expected (allowing for
recurrences and deaths). At baseline, 77% of forms were returned,
decreasing to 71% after 2 years and to 50% after 5 years.
Completeness of forms
The EORTC QLQ-C30 items were very well completed up to 2
years, with at most two missing values per dimension in either
treatment group, and at most four missing values per symptom.
The menopausal items 1–5 were generally well completed, with
the exception of the premenopausal group at baseline where about
10% of values were missing. The remaining questions were less
well completed at the early time points.
For the sexual activity questions, although those on page 1 were
well completed (mainly less than 5% missing), many more
responses were provided for the page 2 questions (relevant only
to sexually active patients) than patients stating that they were
sexually active. Analysis excluded patients who said they were not
sexually active at any given time point.
Primary end points
Note that the graphs include all patients who responded at each
time point. Groups are not directly comparable in the graphs as the
groups of patients who responded differ over time. To make
statistical comparisons, we have to consider changes from baseline
for those patients who responded at both baseline and the time in
question.
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For the high-dose group, the median decrease in global QL at 6
months was significantly greater (P¼0.02) than in the conven-
tional group (Figure 1). At 12 months, the median change had
returned to baseline levels in both groups.
Fatigue
For the high-dose group, there was a median increase in fatigue
at 6 months; median levels of fatigue were unchanged in the
conventional group at this time point but not significantly
different from the high-dose group (P¼0.06) (Figure 2). At 12
months, the median fatigue scores had returned to baseline levels
in both groups and continued to fall until 24 months. This lack of
difference in fatigue in the conventional group at 6 months is
surprising and may reflect a lack of sensitivity for picking up
changes in fatigue in the QLQ C30.
QLQ dimensions and symptoms
The only dimension showing a significant difference between
treatment groups in change from baseline was social functioning at
6 months (Po0.002), with patients in the high-dose treatment arm
having lower social functioning scores than the conventional arm
(Figure 3). Both of these scores returned to baseline levels at 12
months and improved on baseline scores (collected following
diagnosis and surgery for breast cancer but before the start of
chemotherapy) from 2 years onwards.
Table 1 Demographic and clinical characteristics of QL patients
QL Study Main study
High dose N¼198 Conventional N¼192 N¼605
Age mean, 95% CI 45 (22, 60) 46 (25, 63) 46 (2, 64)
Menopausal status N % of known N % of known N % of known
Premenopausal 132 67 121 63 400 66
Perimenopausal 23 12 19 10 62 10
Postmenopausal 42 21 51 27 138 23
Missing 1 1 5
Radiation to the breast
Yes 179 95 179 95 547 95
No 10 5 10 5 30 5
Missing 9 3 28
Radiation to the axilla
Yes 39 21 46 24 156 27
No 150 79 143 76 421 73
Missing 9 3 28
Tamoxifen
Yes 152 80 150 79 465 81
No 36 20 39 21 110 19
Missing 10 3 30
Table 2 QL data collected
High dose Conventional All
Time point Expected Returned % Expected Returned % Expected Returned %
Baseline 198 155 78 192 147 77 390 302 77
6 months 194 144 74 185 141 76 379 285 75
1 year 180 136 76 174 124 71 354 260 74
2 years 145 97 68 144 107 74 289 204 71
3 years 124 65 52 128 73 58 252 138 55
4 years 109 57 52 118 64 54 227 121 53
5 years 105 45 44 112 56 52 217 101 50
0
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Figure 1 Global quality of life.
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treatment groups in change from baseline were appetite change
(Po0.001) and constipation (Po0.001) at 6 months. High-dose
patients suffered more appetite loss and less constipation than
conventional patients at this point.
Menopause
Of the women who were premenopausal before entry into the trial,
113 (86%) and 96 (79%) of patients in the high-dose and
conventional groups, respectively, experienced loss of menses
during follow-up. There was no significant difference between the
groups.
Menopausal symptoms
For patients in both groups, night sweats, daytime sweats, hot
flushes and vaginal dryness increased over the first year and
remained significantly above baseline over the 5-year follow-up
(Po0.0001 at each time point). Aches and pains were increased at
6 months (P¼0.0004), 48 months (P¼0.006) and 60 months
(P¼0.002). Weight gain was significantly above baseline up to 2
years (Po0.0001), thereafter there was no significant difference
from baseline. Menstrual problems did not change significantly
over the period, having had a mean score of 1.3 at baseline (where
1¼‘Not at all’ and 2¼‘A little’). Patients’ feelings about their
menstrual state scored a mean of 5.4 at baseline (towards the
relieved end of the scale of 1 to 7) and increased steadily up to a
mean value of 5.9 at 5 years.
The only differences between the two treatment groups were for
aches and pains and weight gain at 6 months (Po0.05). In both
cases, the high-dose group saw smaller changes from baseline than
the conventional group.
Sexual activity
Data on sexual activity over 5 years are presented in Table 3. Of the
patients who responded to the question ‘Do you engage in sexual
activity with anyone at the moment?’, 108 out of 148 (73%) of high-
dose patients and 92 out of 147 (68%) of conventionally treated
patients were sexually active at baseline; the groups were not
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Figure 2 QLQ-30 fatigue score.
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Figure 3 QLQ social functioning score.
Table 3 SAQ activity and dimensions scores
Sexually active % P* Pleasure score P1** P2*** Discomfort score P1 P2 Habit P1 P2
Baseline
All patients 70 13 0 1
6 months
High dose 48 o0.001 9 0.55 o0.001 2 0.23 o0.001 0 0.53 o0.001
Conv 62 0.24 9 1 0
12 months
High dose 62 0.03 11 0.91 0.03 1 0.63 o0.001 0 0.74 0.11
Conv 81 0.45 11 1 1
24 months
High dose 64 0.8 10 na 0.04 1 na o0.001 1 na 1
Conv 64 1 11 1 1
36 months
High dose 70 0.29 9 na 0.02 1 na o0.001 1 na 0.08
Conv 69 1 11 1 1
48 months
High dose 65 0.13 10 na 0.003 2 na o0.001 1 na 0.49
Conv 55 0.58 9 1 1
60 months
High dose 68 0.63 8 na 0.001 2 na o0.001 1 na 0.45
Conv 65 0.69 9 1 1
*P for sexually active: change since baseline per group: McNemar’s test. **P1 for dimension scores: change since baseline difference between groups: Mann–Whitney test. ***P2
for dimension scores: overall change since baseline: Mann–Whitney test.
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activity was significantly lower than baseline at 6 and 12 months
(Figure 4, Pp0.001, P¼0.03), but returned to baseline levels
thereafter. For the conventional group, there were no significant
changes from baseline.
Sexual outcomes
For patients who responded to the questions on sexual pleasure,
the median score was 13 at baseline (Figure 5); the groups were
not significantly different (P¼0.8). The changes from baseline
were not significantly different between the treatment groups at
6 months (P¼0.6) or 12 months (P¼0.9). For both the groups,
pleasure was significantly reduced from baseline at all time points
up to 5 years. When patients were compared by menopausal status
at trial entry, there were no significant differences in pleasure
scores between the two treatment groups.
For patients who responded to the questions on discomfort, the
median score was 0 at baseline; the groups were not significantly
different (P¼0.9). The changes from baseline were not signifi-
cantly different between the treatment groups at 6 months
(P¼0.2) or at 12 months (P¼0.6). For the patients as a whole,
discomfort was significantly increased from baseline at all time
points up to 5 years (Po0.001 at all time points). Again, there were
no significant differences when patients were compared by
menopausal status at trial entry.
Overall patients who responded to the question on frequency of
sexual activity over the past month compared with ‘what is usual
for you’, the median score at baseline was 1 ‘about the same’. The
median score for the high-dose group was 1 at baseline and 0 ‘less
than usual’ for the conventional group; the difference between the
groups was not significant (P¼0.4). The changes from baseline
were not significantly different between the treatment groups at
6 months (P¼0.5) or at 12 months (P¼0.7). For the patients as
a whole, frequency of sexual activity compared with usual was
significantly reduced from baseline at 6 months (Po0.001) but was
similar to baseline at all time points beyond that. At 6 months,
there was a small difference in frequency between pre- and
postmenopausal patients – a larger drop for premenopausal
patients – this suggests that the treatment effect at 6 months is
concentrated in the premenopausal patients. These differences
disappear at 12 months and in subsequent years.
DISCUSSION
The early data collection was probably adequate to draw some
general conclusions about the impact on the QL in the early to
medium term following highdose as compared to conventional
chemotherapy. The important general conclusion is that although
the median decrease in global QL in 6 months was greater in the
high-dose chemotherapy group as compared to the conventional
chemotherapy group, the changes had returned to normal and
were equal to the conventional therapy group by 12 months. Over
the same time period, there was also a trend to increased fatigue
following high-dose chemotherapy but this did not reach
significant levels. Deterioration in social functioning from baseline
was significantly greater in the high-dose cancer group but again
this returned to the same levels as conventional chemotherapy by
12 months, in both groups social functioning scores reached
higher than baseline levels at 2 years. Lower social functioning
scores at baseline were likely to reflect a recent diagnosis of cancer
and breast cancer surgery.
The most persistent changes appear to be in the effect of
treatment on menopausal symptoms and on sexual pleasure, also
reflected in problems with discomfort. These details shown in
Table 3 show that high-dose and conventional chemotherapy have
persisting negative effects on sexual health that may last for several
years following therapy for both pre- and postmenopausal women.
Data on the effect of other hormone-related treatments on sexual
discomfort were not collected and could therefore have influenced
sexual outcomes in this study, both groups had similar levels of
tamoxifen use (80% high dose; 79% conventional treatment). As
over 60% of patients were premenopausal before chemotherapy,
it is likely that some of these problems were associated with
menopausal symptoms. In another study, chemotherapy-induced
menopause has been shown to be related to greater changes in
sexual functioning, although women who were menopausal before
cancer chemotherapy have also reported changes in sexual
function, of a lower order (Lindley et al, 1998).
To the best of our knowledge, changes in sexual pleasure and
discomfort have not been previously reported as a long-term
complication of high-dose chemotherapy. These changes, however,
did not have long-term effects on sexual habit, which appeared to
return to normal frequency and similar to that of conventional
chemotherapy by about 12 months from treatment.
CONCLUSIONS
Overall these results suggest that high-dose chemotherapy had
temporary differentially more potent effects on several areas of QL
and sexual activity in the first 6 months following treatment. These
virtually return to baseline levels of function similar to conven-
tional therapy after this time point. The one exception is sexual
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shealth, with sexual pleasure significantly reduced and discomfort
increased for up to 5 years following both conventional and high-
dose chemotherapy. These results should be reviewed within the
context of the main study (Leonard et al, 2004) that reported no
significant differences between the groups in 5-year relapse-free
survival and overall survival. It would therefore seem that the
increased early toxicities associated with the high-dose therapy are
not balanced by improvements in early 5-year survival.
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